20.3 Medicinal Chemistry Essentials

Structure-Activity Relationship and Selective Toxicity

Structure-activity relationship (SAR) is the study of how a drug's chemical structure determines its biological activity — small changes in a molecule can dramatically alter potency, spectrum, metabolism, or toxicity. Selective toxicity, a concept articulated by Paul Ehrlich, is the principle that an ideal antimicrobial harms the pathogen without harming the host. Most antibiotic classes achieve selective toxicity by targeting structures or pathways present in microbes but absent in humans.

---

Beta-Lactam Antibiotics

The beta-lactam antibiotics — penicillins, cephalosporins, carbapenems, and monobactams — all share a four-membered beta-lactam ring. They bind penicillin-binding proteins (PBPs) and inhibit transpeptidation, the final cross-linking step of peptidoglycan (cell-wall) synthesis. Bacterial lysis follows because the cell wall is weakened.

The basis of selective toxicity is that human cells lack a peptidoglycan cell wall, so the target does not exist in the host.

Penicillin Core

The penicillin nucleus is 6-aminopenicillanic acid (6-APA), consisting of a thiazolidine ring fused to the beta-lactam ring. Modifications of the side chain at C-6 change the drug's properties:

Cephalosporin Core

The cephalosporin nucleus is 7-aminocephalosporanic acid (7-ACA), a beta-lactam ring fused to a dihydrothiazine ring. Successive generations progressively expand Gram-negative coverage while retaining or reducing Gram-positive activity:

• 1st generation (cefalexin, cefazolin) — Gram-positive strong
• 2nd generation (cefuroxime) — balanced
• 3rd generation (ceftriaxone, cefotaxime, ceftazidime) — Gram-negative, CNS penetration
• 4th generation (cefepime) — broad including Pseudomonas
• 5th generation (ceftaroline) — MRSA coverage

---

Sulfonamides and Trimethoprim: Sequential Folate Blockade

Bacteria must synthesise folate de novo; humans obtain folate from the diet and cannot synthesise it. This difference is the basis of selective toxicity.

• Sulfonamides (e.g. sulfamethoxazole) are structural analogs of PABA (para-aminobenzoic acid). They competitively inhibit dihydropteroate synthase (DHPS), the enzyme that condenses PABA with pteridine to form dihydropteroate — an early step in folate synthesis.
• Trimethoprim inhibits dihydrofolate reductase (DHFR), a later step that converts dihydrofolate to tetrahydrofolate.

Combining sulfamethoxazole with trimethoprim (co-trimoxazole) produces sequential blockade of two consecutive steps in the same pathway, yielding synergistic bactericidal activity.

---

Fluoroquinolones

Fluoroquinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin) share the quinolone pharmacophore and target bacterial DNA gyrase (topoisomerase II in Gram-negatives) and topoisomerase IV (in Gram-positives), blocking DNA replication and repair. Mammalian topoisomerases are structurally different enough to spare host cells.

---

Protein-Synthesis Inhibitors

Ribosomes are a rich target for selective toxicity because bacteria have 70S ribosomes (30S + 50S subunits) while humans have 80S ribosomes (40S + 60S).

---

Statins: HMG-CoA Reductase Inhibitors

Statins (e.g. atorvastatin, simvastatin, rosuvastatin) inhibit HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis that converts HMG-CoA to mevalonate. The statin pharmacophore is structurally analogous to the transition state of mevalonate, allowing competitive inhibition at the active site. This is a classic example of rational medicinal chemistry: the drug is a mevalonate mimic.

---

Resistance Mechanisms

Understanding resistance helps the exam because it links structure to clinical failure. Beta-lactam resistance most commonly arises through beta-lactamase enzymes that hydrolyse the beta-lactam ring. MRSA carries the mecA gene encoding a low-affinity PBP2a, so meticillin and most beta-lactams cannot bind effectively. Carbapenemases (e.g. KPC, NDM-1) confer broad resistance including to carbapenems. Beta-lactamase inhibitors such as clavulanate, tazobactam, and avibactam restore activity by suicidally inhibiting the enzyme, which is why amoxicillin-clavulanate and piperacillin-tazobactam are common exam pairings.

Fluoroquinolone resistance arises through target mutations in DNA gyrase (gyrA) and topoisomerase IV (parC) and through efflux pumps. Macrolide resistance commonly arises via erm-mediated methylation of the 23S rRNA target* (MLS_B cross-resistance) or mef-mediated efflux*.

---

Pharmacophore Concept

A pharmacophore is the three-dimensional arrangement of steric and electronic features a molecule needs to bind a specific biological target and elicit a response. Recognising a shared pharmacophore helps predict class effects and cross-allergy. Examples on the blueprint:

• Beta-lactam pharmacophore (four-membered lactam ring) — shared by penicillins, cephalosporins, carbapenems, monobactams → shared allergy risk
• Quinolone pharmacophore (4-quinolone core with a fluorine at C-6 in fluoroquinolones) → class cross-resistance
• Statin pharmacophore (mevalonate transition-state mimic) → HMG-CoA reductase inhibition
• Sulfonamide pharmacophore (PABA mimic) → folate-synthesis inhibition

---

Exam Pearls

• Selective toxicity arises from absent host targets (cell wall, 70S ribosome, DNA gyrase, DHPS) or differences in affinity (fungal ergosterol vs mammalian cholesterol).
• Co-trimoxazole is the canonical example of sequential blockade.
• Tetracyclines and aminoglycosides both bind 30S but cause very different toxicities — do not confuse them.
• Cross-allergy within the beta-lactam class depends on the side chain; penicillins and cephalosporins share partial cross-reactivity (about 1-10%), monobactams (aztreonam) largely do not, and carbapenems have low cross-reactivity.
• When asked why a drug is safe for humans, the answer is almost always that the target is absent in humans (cell wall, DHPS, DNA gyrase, 70S ribosome) or different in affinity (HMG-CoA reductase, fungal ergosterol).